UK MHRA does not favour introducing additional pre-market scrutiny for high-risk devices in EU
This article was originally published in Clinica
Executive Summary
The Medicines and Healthcare products Regulatory Agency has told a UK parliamentary committee that it does not support the concept of introducing pre-market scrutiny for high-risk devices marketed in the EU in addition to that undertaken by notified bodies.